A social post points to a Phase 3 obesity trial where people on the highest retatrutide dose lost 28.3% on average, and hints at benefits beyond weight loss.
Recap by typeshit. Post by Facebook on Facebook.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dissolving strips are showing up in the peptide market. The Bee asks the FDA and researchers whether they are safe and actually work.
The grant funds a 12 month quality improvement project built into electronic health records. The post doesn't say how it connects to Lilly's GLP-1 drugs.
Loading…